Shigella is the leading bacterial cause of diarrheal mortality in children and can cause long-term effects on growth and development. No licensed Shigella vaccines currently exist but several promising candidates are in development and could be available in the next five years. Despite Shigella being a well-known public health target of the World Health Organization for decades, given current burden estimates and competing preventable disease priorities in low-income settings, whether the availability of an effective Shigella vaccine will lead to its prioritization and widespread introduction among countries at highest risk is unknown. We conducted a mixed-methods study of national stakeholders and healthcare providers in five countries in Asia and Africa and regional stakeholders in the Pan American Health Organization to identify preferences and priorities for forthcoming Shigella vaccines. In our study of 89 individuals, diarrhea was the most frequently mentioned serious health concern for children under five years. Antimicrobial resistance (AMR) was more often considered very concerning than diarrhea or stunting. Shigella awareness was high but not considered a serious health concern by most stakeholders. Most participants were willing to consider adding a new vaccine to the routine immunization schedule but expressed reservations about a Shigella vaccine because of lower perceived burden relative to other preventable diseases and an already crowded schedule; interest was highest among national stakeholders in countries receiving more financial support for immunization. The priority of a Shigella vaccine rose when participants considered vaccine impacts on reducing stunting and AMR. Participants strongly preferred oral and combination vaccines compared to injectable and a single-antigen presentations, citing greater perceived community acceptability. This study provides a critical opportunity to hear directly from country and regional stakeholders about health priorities and preferences around new vaccines. These findings should inform ongoing Shigella vaccine development efforts and eventual vaccine introduction and implementation planning.
Reaching the Sustainable Development Goal 2030 global mortality and morbidity targets will require increased access to essential health services. Scaling high-impact health interventions within the public sector is complex; delineation of the pathway to scale for each intervention within each distinct geography is important for prioritising actions to advance interventions towards effective coverage. Following a review of 38 theoretical frameworks describing pathways for scaling health system interventions, we developed, tested and refined a new schema—the Stages of Achieving Effective Coverage and Equity Framework—for use to describe the status of policy adoption, implementation and coverage of key maternal, newborn, child health and nutrition (MNCHN) interventions. We propose a framework with six domains (global, national, systems, implementation, availability and coverage) covering 26 critical milestones with identified corresponding, intervention-specific indicators. Our framework was validated by the alignment of over 83 000 data points sourced from document review, interviews and global or country surveys. Visualisations are presented to highlight how the framework is operationalised to assess scale-up progress. We outline our process of conceptualising and developing a new framework and articulate its use case for action-oriented monitoring of progress towards effective coverage through applied examples in key geographies. Our framework offers an easy-to-follow implementation pathway and a set of common policy and implementation indicators to monitor scale-up towards effective coverage that uses existing secondary data sources where available. Achieving prioritised maternal, newborn and child health targets requires scalable implementation strategies for lifesaving interventions, alongside monitoring progress towards achieving scale.
Maternal immunization against respiratory syncytial virus (RSV) offers a promising strategy to reduce severe respiratory infections and hospitalizations am
Background/Objectives: Globally, coverage of the hepatitis B vaccine within 24 h of birth is 45 percent, far below the WHO target of 90 percent by 2030. For newborns delivered in out-of-facility settings, delayed contact with health workers, transportation barriers, and cold chain constraints can impede timely vaccination. This review explores strategies and facilitators for delivering birth dose vaccines to infants born outside of health facilities in low- and middle-income countries. Methods: A rapid scoping review was conducted, searching PubMed and targeted websites for peer-reviewed and gray literature published between 2005 and 2025. Data were charted using a standardized extraction tool. Frequency and thematic analyses were conducted. Results: After screening 315 studies, 26 eligible sources were identified. Delivery strategies consisted of three components: identifying and tracking home births; supporting caregiver uptake through education, reminders, or incentives; and delivering the vaccine through home-based administration or referral to facilities. Sub-components included pregnancy and birth notification systems, postnatal home visits, mobile reminders, incentives, and home-based vaccination by facility or community providers. The feasibility of these strategies was shaped by factors across system levels, such as national policies and financing; health system infrastructure; cold chain capacity; health workforce configuration; caregiver awareness; and community social norms. In several contexts, flexible cold chain approaches and vaccine administration by community-based cadres enabled timely vaccination of infants born at home. Conclusions: Vaccination programs can learn from existing out-of-facility vaccine delivery approaches to strengthen hepatitis B birth dose vaccination programs for timely and equitable coverage.
The Latin American and Caribbean region (LAC) has historically been an early adopter of new vaccines, including the recently introduced maternal vaccine to protect infants against respiratory syncytial virus (RSV). Since maternal RSV vaccination requires gestational age (GA)-specific administration, antenatal care (ANC)-based delivery feasibility depends on ANC visit timing and frequency. We assessed ANC attendance relative to recommended vaccination windows in four LAC countries to inform planning for maternal RSV vaccine implementation and future maternal immunization programs. We conducted a retrospective, cross-sectional analysis from Perinatal Information System data across eight tertiary facilities in Bolivia, Ecuador, Honduras, and Uruguay. Women 15-45 years old with ≥1 ANC visit in 2023 and a live, singleton birth at a study facility were included. GA per visit was extracted or derived from last menstrual period or birth data. We defined RSV vaccination eligibility according to Pan American Health Organization (PAHO) (32-36 weeks) and World Health Organization (WHO) (≥ 28 weeks) recommendations. Descriptive analyses summarized ANC initiation, visit timing, and the proportion of women attending visits within eligibility windows. We included 37,604 women. The median GA at ANC initiation was 12 weeks, ranging from 10 weeks (Uruguay) to 15 weeks (Ecuador). Overall, 63.5% of women attended at least one ANC visit during the PAHO window, with country-specific proportions from 53.6% (Honduras) to 82.3% (Uruguay). Attendance within the WHO window was higher (91.4%). Median ANC attendance was five visits, ranging from five (Honduras) to eight (Uruguay). Earlier ANC initiation was associated with higher visit counts. There is substantial potential for achieving high maternal RSV vaccine coverage in LAC, particularly per broader WHO vaccine recommendations. Where ANC begins later or visits are fewer, narrower vaccine-eligible windows may limit achievable coverage. Strengthening early ANC engagement and immunization counseling may increase vaccination opportunities.